Waddell & Reed Financial Inc. Has $49.73 Million Position in Humana Inc (NYSE:HUM)

Waddell & Reed Financial Inc. cut its holdings in Humana Inc (NYSE:HUM) by 1.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 167,100 shares of the insurance provider’s stock after selling 2,800 shares during the period. Waddell & Reed Financial Inc. owned about 0.12% of Humana worth $49,734,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its holdings in shares of Humana by 12.7% in the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after purchasing an additional 1,374,030 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Humana by 1.7% in the first quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock valued at $3,276,068,000 after purchasing an additional 198,588 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Humana by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,564,251 shares of the insurance provider’s stock valued at $420,503,000 after purchasing an additional 11,915 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Humana by 7.6% in the second quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after purchasing an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Humana by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 768,245 shares of the insurance provider’s stock worth $228,653,000 after buying an additional 26,303 shares during the last quarter. Institutional investors own 92.99% of the company’s stock.

A number of equities analysts recently weighed in on HUM shares. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 target price on the stock in a report on Thursday, October 4th. Credit Suisse Group boosted their target price on shares of Humana from $350.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, September 4th. Piper Jaffray Companies restated a “buy” rating and set a $355.00 target price on shares of Humana in a report on Thursday, August 2nd. Cowen started coverage on shares of Humana in a report on Monday, September 17th. They set a “market perform” rating and a $372.00 target price on the stock. Finally, Morgan Stanley started coverage on shares of Humana in a report on Thursday, July 12th. They set an “overweight” rating and a $362.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $339.79.

In other news, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the completion of the sale, the insider now owns 14,289 shares of the company’s stock, valued at $4,715,370. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Cynthia H. Zipperle sold 4,886 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $321.89, for a total transaction of $1,572,754.54. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,284 shares of company stock valued at $13,147,715. Company insiders own 0.60% of the company’s stock.

HUM stock opened at $333.66 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. Humana Inc has a one year low of $231.90 and a one year high of $341.30. The firm has a market cap of $46.64 billion, a price-to-earnings ratio of 28.49, a P/E/G ratio of 1.69 and a beta of 0.97.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping the Zacks’ consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The firm had revenue of $14.26 billion during the quarter, compared to analysts’ expectations of $14.16 billion. During the same period in the previous year, the business posted $3.49 earnings per share. As a group, sell-side analysts anticipate that Humana Inc will post 14.18 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be given a dividend of $0.50 per share. The ex-dividend date is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.60%. Humana’s dividend payout ratio (DPR) is 17.08%.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: What Does Beta Mean In Stock Selection

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply